What's Wrong With Access: How the SEC's Proposed Rules on Shareholder Access to Proxy Statements Miss the Mark

This episode features a conversation with Jesse Neil. Jesse is a healthcare attorney in Foley’s Nashville office. In this discussion, he reflects on growing-up in Nashville, TN, attending the University of North Carolina at Chapel Hill for undergrad and the University of Mississippi School of Law.

These trends included (i) an enduring focus on waste, fraud, and abuse in the health care industry; (ii) a continued focus on Medicare Advantage and a newer focus on gender transition procedures for minors; and (iii) the ever-increasing use of data analytics to prosecute cases.

On April 1, 2026,the U.S. Food & Drug Administration (FDA) issued a statement clarifying its compliance policy on the  conditions that must be met for compounded drugs to qualify for the exemptions under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).